A six-month supported online programme for the treatment of persecutory delusions: Feeling Safer
Freeman D., Isham L., Freeman J., Rosebrock L., Kabir T., Kenny A., Diamond R., Beckley A., Rouse N., Ahmed M., Hudson F., Sokunle G., Waite F.
Background: Based on an efficacious face-to-face theory-driven psychological therapy for persecutory delusions in the context of psychosis, we set out to develop a scalable guided six-month online programme. The aim was an intervention that patients can easily access and use, produces large clinical effects, and can be supported by a range of mental health professionals in less contact time than faceto-face therapy. We report here the proof-of-concept clinical testing. At least moderate-sized clinical effects were required to progress to a randomised controlled trial. Methods: In the six-month Feeling Safer online programme, a certified medical device, patients complete a brief assessment and then are provided with up to ten modules that match their difficulties. As the patient progresses through the programme, regular remote meetings with a mental health professional take place. These may be supplemented by in-person visits. A pre- to post-treatment cohort trial was conducted with fourteen patients with persistent persecutory delusions. The primary outcome was the Psychotic Symptoms Rating Scale (PSYRATS)-Delusions. Results: Satisfaction and usability ratings of the programme were high. Very large reductions in persecutory delusions were observed (PSYRATS mean reduction=7.1, 95% C.I.=3.4, 10.8, n=13, Cohen’s d=3.0). There were large improvements in paranoia, anxiety, depression, agoraphobic distress, psychological wellbeing, meaningful activity, personal recovery, recovering quality of life, and moderate improvements in insomnia, agoraphobic avoidance, and quality of life. Conclusions: The clinical effects associated with Feeling Safer were very high, comparable to those seen in the evaluations of the face-to-face therapy, and enable progression to a randomised controlled trial.